NASDAQ:LEXX

Lexaria Bioscience Q2 2025 Earnings Results & Report

Lexaria Bioscience logo
$4.26 -0.15 (-3.31%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexaria Bioscience beat analyst expectations on both earnings and revenue in its Q2 2025 results, released April 14, 2025. The company reported EPS of -$2.25 versus the -$2.40 consensus estimate, while revenue of $174 thousand topped the $137 thousand estimate by $37.00 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Lexaria Bioscience EPS Results

Actual EPS
-$2.25
Consensus EPS
-$2.40
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Lexaria Bioscience Revenue Results

Actual Revenue
$174 thousand
Expected Revenue
$137 thousand
Beat/Miss
Beat by +$37.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Lexaria Bioscience's Q4 2026 earnings is estimated for Tuesday, November 24, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 23, 2026 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Lexaria Bioscience Q2 2025 Earnings FAQ

Lexaria Bioscience (NASDAQ:LEXX) reported earnings of -$2.25 per share for Q2 2025, beating the consensus estimate of -$2.40. The report was announced on Monday, April 14, 2025.

Lexaria Bioscience reported revenue of $174 thousand for Q2 2025, against a consensus estimate of $137 thousand.

Lexaria Bioscience's next earnings date is estimated for Tuesday, November 24, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexaria Bioscience on the company's earnings history page.

Lexaria Bioscience Earnings Headlines

Lexaria Bioscience (LEXX) Projected to Release Earnings on Tuesday
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
LEXX: Introducing DehydraTECH 3.0
Lexaria Bioscience advances 12% on Australian tax rebate
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics.

The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments. These programs are investigational; Lexaria’s work includes laboratory and clinical research rather than a broad portfolio of approved medicines.

Based in British Columbia, Canada, Lexaria focuses on developing and licensing its delivery technology and advancing research with pharmaceutical ingredients. The company has also developed consumer products in the past, including hemp-derived products, but its current activities center on DehydraTECH research and development.

View Lexaria Bioscience Profile